Bank of America Corp DE Boosts Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Bank of America Corp DE raised its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 222.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 98,245 shares of the company's stock after buying an additional 67,772 shares during the quarter. Bank of America Corp DE owned about 0.18% of Zevra Therapeutics worth $819,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. raised its holdings in Zevra Therapeutics by 462.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company's stock valued at $30,441,000 after acquiring an additional 3,001,000 shares during the last quarter. AIGH Capital Management LLC acquired a new position in Zevra Therapeutics in the fourth quarter valued at $6,577,000. Barclays PLC lifted its position in Zevra Therapeutics by 402.9% during the fourth quarter. Barclays PLC now owns 289,688 shares of the company's stock worth $2,416,000 after buying an additional 232,089 shares during the period. Altium Capital Management LLC boosted its stake in Zevra Therapeutics by 8.8% in the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company's stock worth $15,429,000 after buying an additional 150,000 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Zevra Therapeutics by 13.8% in the 4th quarter. Geode Capital Management LLC now owns 1,188,120 shares of the company's stock valued at $9,912,000 after buying an additional 144,256 shares during the period. Hedge funds and other institutional investors own 35.03% of the company's stock.

Insider Buying and Selling at Zevra Therapeutics

In other news, Director John B. Bode bought 10,000 shares of Zevra Therapeutics stock in a transaction dated Wednesday, March 19th. The shares were acquired at an average cost of $7.96 per share, with a total value of $79,600.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at approximately $318,400. This trade represents a 33.33% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ZVRA has been the topic of several recent analyst reports. JMP Securities set a $18.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research note on Thursday, March 13th. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Finally, Wall Street Zen upgraded Zevra Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $22.29.

Zevra Therapeutics Stock Down 0.1%

NASDAQ ZVRA traded down $0.01 during trading hours on Thursday, hitting $9.37. The company had a trading volume of 480,071 shares, compared to its average volume of 662,613. The firm's 50 day moving average is $7.87 and its 200 day moving average is $8.08. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. Zevra Therapeutics, Inc. has a fifty-two week low of $4.20 and a fifty-two week high of $9.76. The company has a market capitalization of $512.35 million, a price-to-earnings ratio of -4.76 and a beta of 2.01.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. The business had revenue of $20.40 million during the quarter, compared to analyst estimates of $16.96 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter last year, the firm earned ($0.40) earnings per share. Sell-side analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.